Deutsche Bank
KLRS

Deutsche Bank’s Kalaris Therapeutics KLRS Stock Holding History

Deutsche Bank’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,076
Closed -$53.8K – 3720
2024
Q1 		$53.8K Buy
3,076
+2,137
+228% +$34.9K ﹤0.01% 3375
2023
Q4 		$14.7K Hold
939
– – ﹤0.01% 3515
2023
Q3 		$46.4K Hold
939
– – ﹤0.01% 3422
2023
Q2 		$73.4K Buy
939
+79
+9% +$7.51K ﹤0.01% 3387
2023
Q1 		$77.9K Buy
860
+218
+34% +$27.8K ﹤0.01% 3423
2022
Q4 		$75.8K Buy
642
+9
+1% +$1.53K ﹤0.01% 3446
2022
Q3 		$115K Sell
633
-126
-17% -$19.6K ﹤0.01% 3247
2022
Q2 		$69K Sell
759
-349
-31% -$36.6K ﹤0.01% 3665
2022
Q1 		$172K Sell
1,108
-39
-3% -$7.78K ﹤0.01% 3350
2021
Q4 		$342K Sell
1,147
-67
-6% -$31.1K ﹤0.01% 3071
2021
Q3 		$700K Buy
1,214
+133
+12% +$61.6K ﹤0.01% 2840
2021
Q2 		$491K Sell
1,081
-59
-5% -$30.5K ﹤0.01% 3230
2021
Q1 		$613K Buy
1,140
+329
+41% +$276K ﹤0.01% 2974
2020
Q4 		$717K Buy
811
+286
+54% +$220K ﹤0.01% 2669
2020
Q3 		$332K Buy
+525
New +$359K ﹤0.01% 2899

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's KLRS Position: Q2 2024 in Review

Deutsche Bank sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 3,076 shares — an estimated $53.8K sold.

Deutsche Bank first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $717K in Q4 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Deutsche Bank reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Deutsche Bank sold 3,076 Kalaris Therapeutics shares in Q2 2024, an estimated $53.8K.
  • Deutsche Bank first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
  • Deutsche Bank's Kalaris Therapeutics position peaked at $717K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Deutsche Bank's 13F filing for Q2 2024, filed 14 Aug 2024.